ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries

We specialise in the strategic development, management and analysis of programs that support Clinical Development - from compound selection to Phase I-IV clinical studies.

  • Headquarters: Dublin, Ireland
  • Financial information: ICON’s revenues for FY ending 31 December 2017 was US$1.758 billion. ICON trades on the Nasdaq exchange.
  • Employee numbers: ICON currently has 13,650 employees in 93 offices in 37 countries.

Products and services

ICON offers a broad range of specialised services to assist pharmaceutical, biotechnology and medical device companies to bring new treatments to market faster. Our services span the entire lifecycle of product development and can be adapted to suit small local trials or large global programs.

  • Phase I-IV Clinical Trial Design, Management and Review
  • Clinical Pharmacology
  • Bioanalytical Laboratory Services
  • Clinical Pathology
  • Protocol Design
  • Biomarker Services
  • Pharmacodynamic/Pharmacokinetic Analysis
  • Data Management
  • Medical and Safety Services
  • Health Economics & Outcomes Research
  • Due diligence support
  • Payer Engagement Services
  • Consulting
  • Medical Device & Diagnostic Research
  • Patient and Investigator Portals
  • Biostatistics
  • Interactive Technologies – IVR, IWR, ePRO
  • Patient Recruitment
  • Medical Imaging
  • Global Central Laboratory Services
  • Medical Writing
  • Program Management
  • Contract Resourcing
  • Strategic Pricing
  • Market Access
  • Value Strategy
  • Adaptive Trials
  • Patient Centric Monitoring
  • eConsent

Key Company Milestones

1990 -  ICON founded in Dublin, Ireland, by Dr. John Climax and Dr. Ronan Lambe
1991 - ICON opens first overseas office in Winchester, UK
1992 - ICON opens first US office in Philadelphia
1996 - ICON opens first Asia-Pacific office in Japan
1998 - ICON begins trading as a public company on the Nasdaq exchange
1998 - ICON opens office in Singapore and Buenos Aries, Argentina
2000 - ICON acquires UK-based regulatory consultancy
2000 - ICON acquires Central Laboratory in New York
2002 - ICON acquires Managed Clinical Solutions
2003 - ICON acquires Medeval Group Ltd, a UK-based Phase I facility
2003 - ICON acquires Globomax
2004 - ICON acquires Beacon Bioscience Inc.
2006 - ICON acquires Ovation
2007 - ICON acquires DOCS International
2007 - ICON Named “Favourite Contract Research Organisation” by pharmaceutical and biotech firms in independent survey by William Blair & Company and Thompson CenterWatch
2008 - ICON acquires Healthcare Discoveries LLC
2008 - ICON acquires Prevalere Life Sciences Inc
2008 - ICON opens Central Laboratory in Bangalore, India
2008 - ICON signs strategic agreement with Lilly to manage Lilly’s clinical Data Management business in over 36 countries
2009 - ICON Recognised as Clinical Research Company of the year at the PharmaTimes Awards
2009 - ICON opens new clinical pharmacology unit in Omaha, Nebraska, US
2009 - ICON acquires Veeda Laboratories Ltd.
2010 - ICON acquires Timaq Medical Imaging
2011 - ICON acquires Oxford Outcomes Ltd.
2011 - ICON acquires Firecrest Clinical Ltd.
2011 - ICON acquires BeijingWits Medical Consulting Ltd
2012 - ICON acquires PriceSpective LLC
2013 - ICON acquires ClinForce and Assent Consulting, Staffing and FSP providers
2013 - ICON acquires Akos an EU Provider of Pharmacovigilance and Drug Safety Services.
2014 - ICON acquires Aptiv Solutions
2015 - ICON creates new global innovation hub in Ireland to advance clinical development
2015 - ICON acquires MediMedia Pharma Solutions
2015 - ICON forms partnership with Mereo BioPharma for clinical development
2015 - ICON acquires PMG Research Inc
2016 - ICON acquires ClinicalRM
2016 - ICON selected by Genomics England to support the world's largest genome sequencing project
2016 - ICON selected by ICHOM to develop world’s first global healthcare outcomes benchmarking programme
2017 - ICON Acquires Mapi Group